News & Updates
Filter by Specialty:

Semaglutide may improve NYHA functional class in obesity-related HFpEF
Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) treated with semaglutide are more likely to show an improvement in NYHA functional class at 52 weeks than those who received placebo, according to a study.
Semaglutide may improve NYHA functional class in obesity-related HFpEF
15 Jul 2024
Complete revascularization after MI reduces mortality, cardiac events
Patients who undergo complete revascularization with percutaneous coronary intervention following a myocardial infarction (MI) are at lower risk of all-cause mortality, cardiovascular mortality, MI, major adverse cardiac events (MACE), and repeat revascularization, reports a recent study.
Complete revascularization after MI reduces mortality, cardiac events
14 Jul 2024
Weight loss surgery delivers lasting quality-of-life benefits for people with T2D, obesity
In the treatment of patients with type 2 diabetes (T2D) and obesity, metabolic/bariatric surgery appears to produce sustained weight loss over 12 years, translating to better physical function, general health, and vitality, as well as reduced pain, according to long-term data from the ARMMS-T2D Study.